Tango Therapeutics (TNGX) Receivables (2020 - 2022)

Tango Therapeutics has reported Receivables for 3 years, with the latest figure at $2.0 million in Q4 2022.

• For the quarter ending Q4 2022, Receivables changed 0.0% year-over-year to $2.0 million; the trailing twelve-month figure through Dec 2022 stood at $2.0 million (changed 0.0% YoY), and the FY2022 full-year result was $2.0 million, changed 0.0% from the prior year.
• Receivables for Q4 2022 stood at $2.0 million, roughly flat from $2.0 million in the prior quarter.
• The five-year high for Receivables was $8.0 million in Q3 2021, with the low at $2.0 million in Q4 2020.
• Average Receivables over 3 years is $2.9 million, with a median of $2.0 million recorded in 2020.
• Year-over-year, Receivables changed 0.0% in 2021 and sank 75.0% in 2022.
• Tracing TNGX's Receivables over 3 years: stood at $2.0 million in 2020, then changed by 0.0% to $2.0 million in 2021, then changed by 0.0% to $2.0 million in 2022.
• The last three Receivables figures came in at $2.0 million (Q4 2022), $2.0 million (Q3 2022), and $2.0 million (Q2 2022), per Business Quant data.

Peer Comparison